| Literature DB >> 28797251 |
Min Li1,2, Xue Xu1, Xinyu Yang1,2, Joey S W Kwong3, Hongcai Shang4,5.
Abstract
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of premature death throughout the world. An estimated 17.5 million people died from CVD in 2012, representing 31% of all global deaths. Nardostachys chinensis (NC), a typical traditional Chinese medicine (TCM), plays a crucial role in the management of patients with CVD, especially for those with cardiac arrhythmia. The purpose of this study was to evaluate the cardioprotective and antiarrhythmic effects of NC in animal and cell experiments.Entities:
Keywords: Animal experiments; Antiarrhythmic effects; Cardioprotective effects; Cell experiments; NC; Nardostachys chinensis
Mesh:
Substances:
Year: 2017 PMID: 28797251 PMCID: PMC5553922 DOI: 10.1186/s12906-017-1910-1
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
The detailed information of the animal experiments
| Study | Species | Weight(g) | Random | Groups | Outcome measure |
|---|---|---|---|---|---|
| Tao Yang et al. 2012 | SD rats | 200 ± 20 | Not mentioned | The sham group ( | IL-6, TNF-ɑ, CK-MB, cTNT, Infarct size, The frequency and time of cardiac arrhythmia |
| Rajakannu Subashini et al. 2006 | Wistar rats | 120–130 | Not mentioned | The control group ( | Body weight; Heart weight; LDH; CPK; AST; ALT; SOD; CAT; GPx; GST; LPO |
I/R Ischaemia-Reperfusion, IL-6 Interleukin-6, TNF-ɑ Tumour Necrosis Factor, CK-MB Creatine kinase-MB, LDH Lactate dehydrogenase, CPK Creatine phosphokinase, AST Aspartate aminotransaminase, ALT Alanine aminotransaminase, SOD Superoxide dismutase, CAT Catalase, GPx Glutathione peroxidase, GST Glutathione-S-transferase, LPO Lipid peroxide
The detailed information of the cell experiments
| Study | Cell | Intervention | Groups | Target | Outcome measure |
|---|---|---|---|---|---|
| Xiangyu Li et al. 2013 | The normal isolated ventricular myocytes of rats | The volatile oil of NC | The volatile oil of NC group-1 (1 μg/g) | Ik; Ik1 | Dose-response; I-V curve; Activation curve; Inactivation curve |
| Qizhu Tang et al. 2004 | The normal isolated ventricular myocytes of rabbits | The extract of NC | The control group | INa; ICa-L | Dose-response; I-V curves |
| Ming Cao et al. 2010 | The normal isolated ventricular myocytes of rats | The volatile oil of NC | The volatile oil of NC group-1 (3 μg/g) | ICa-L | Dose-response; I-V curve; Activation curve; Inactivation curve |
| Yuanwei Liu et al. 2009 | The normal isolated ventricular myocytes of rats | The extract of NC | The control group | INa; Ito | I-V curve |
| Tao Yang et al. 2009 | The normal isolated ventricular myocytes of rats | The volatile oil of NC | The volatile oil of NC group-1 (1 μg/g) | INa | Dose-response; I-V curve; Activation curve; Inactivation curve |
| Langjie Hu et al. 2009 | The normal isolated ventricular myocytes of rats | The volatile oil of NC | The volatile oil of NC group-1 (3 μg/g) | Ito | Dose-response; I-V curve; Activation curve; Inactivation curve |
| Yuzhi Ge et al. 2009 | Nav 1.5-HEK cell | The volatile oil of NC | The volatile oil of NC group-1 (3 ppm) | INa | Dose-response; Voltage-dependent curve |
| Zhiting Wu et al. 2009 | Nav 1.5-HEK cell | The volatile oil of NC | The volatile oil of NC group (10 ppm) | INa | I-V curve; G-V curve |
| Yanyang Liu et al. 2013 | Nav 1.5-HEK cell | The volatile oil of NC | The volatile oil of NC group (5 ppm) | INa | Frequency-dependent curve |
I-V Current-voltage relationship, G-V Conductance-voltage relationship
The information of dose-response
| Study | Xiangyu Li et al. 2013 | Xiangyu Li et al. 2013 | Ming Cao et al. 2010 | Tao Yang et al. 2009 | Langjie Hu et al. 2009 |
|---|---|---|---|---|---|
| Type | Ik | Ik1 | ICa-L | INa | Ito |
| Inhib-ition Ratio | 1 μg/g (10.45 ± 1.14)% | 1 μg/g (5.78 ± 1.32)% | 3 μg/g (11.18 ± 1.48)% | 1 μg/g (7.2 ± 4)% | 3 μg/g (27.01 ± 6.93)% |
The detailed information of the activation curve
| Study | Type | Dose | Number | Half of the activating voltage (mV) | Slope factor | ||
|---|---|---|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | ||||
| Xiangyu Li et al. 2013 | Ik | 5 μg/g | 6 | 23.65 ± 0.65 | 28.19 ± 0.57* | 6.09 ± 0.56 | 5.14 ± 0.51* |
| Ming Cao et al. 2010 | ICa-L | 10 μg/g | 5 | −5.47 ± 0.50 | −2.77 ± 0.49* | 4.68 ± 0.39 | 4.50 ± 0.40 |
| Tao Yang et al. 2009 | INa | 5 μg/g | 6 | −43.65 ± 0.98 | −40.25 ± 1.01* | 5.63 ± 0.75 | 5.03 ± 0.80* |
| Langjie Hu et al. 2009 | Ito | 6 μg/g | 5 | 36.06 ± 1.79 | 34.79 ± 3.03 | 22.97 ± 1.49 | 30.79 ± 2.90 |
*means P < 0.05
The detailed information of the inactivation curve
| Study | Type | Dose | Number | Half of the activating voltage (mV) | Slope factor | ||
|---|---|---|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | ||||
| Xiangyu Li et al. 2013 | Ik | 5 μg/g | 6 | −64.46 ± 1.02 | −82.84 ± 1.27* | 14.40 ± 1.13 | 13.35 ± 1.06* |
| Ming Cao et al. 2010 | ICa-L | 10 μg/g | 5 | −20.82 ± 0.48 | −29.44 ± 1.03* | 6.16 ± 0.43 | 11.05 ± 0.86* |
| Tao Yang et al. 2009 | INa | 5 μg/g | 6 | −100.92 ± 0.68 | −111.20 ± 0.86* | 10.33 ± 0.62 | 11.33 ± 0.74* |
| Langjie Hu et al. 2009 | Ito | 6 μg/g | 5 | −33.74 ± 0.48 | −40.54 ± 0.70* | 5.00 ± 0.40 | 8.42 ± 0.62* |
Note the following: * means P < 0.05
The detailed information of the animal experiment
| Study | Species | Weight(g) | Random | Groups | Outcome measure |
|---|---|---|---|---|---|
| Peng Jian et al. 2015 | Wistar rats | 200 ± 20 | Random digits table | The normal group ( | HR; Heart coefficient; LVSP; LVEDP; +dp/dtmax; −dp /dtmax; cAMP; PKA |
| Jing Zhang et al. 2014 | SD rats | 280–310 | Not mentioned | The control group ( | PVCs; VTs; VFs; HR; MAP; P-R interval; QRS interval; Q-T interval; Cx43; Infarct size of the left ventricular |
| Ping Zhou et al. 2007 | Wistar rats | 250 ± 50 | Not mentioned | The control group-1 ( | ERP; ERP/RR |
HR Heart rate; Heart coefficient = Heart weight (mg)/rat weight(g); LVSP Left ventricular systolic pressure, LVEDP Left ventricular end-diastolic pressure, cAMP Cyclic adenosine monophosphate, PKA Protein kinase A, PVCs Premature ventricular contractions, VTs Ventricular tachycardias, MAP Mean arterial pressure; VFs Ventricular fibrillations, Cx43 Connexin 43, ERP Effective refractory period
Assessment of the risk of bias for animal studies
| Studies | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Tao Yang et al. 2012 | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Unclear | Unclear |
| Rajakannu Subashini et al. 2006 | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Unclear | Unclear |
| Peng Jian et al. 2015 | Yes | Yes | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Unclear | Unclear |
| Jing Zhang et al. 2014 | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Unclear | Unclear |
| Ping Zhou et al. 2007 | Unclear | Yes | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Unclear | Unclear |
Selection bias (sequence generation); 2. Selection bias (baseline characteristics); 3. Selection bias (allocation concealment); 4. Performance bias (random housing); 5. Performance bias (blinding); 6. Detection bias (random outcome assessment); 7. Detection bias (blinding); 8. Attrition bias (incomplete outcome data); 9. Reporting bias (selective outcome reporting); 10. Other (other sources of bias)